CLDI CALIDI BIOTHERAPEUTICS INC revenue, earnings and financials
For the quarter ended June 30, 2026, CALIDI BIOTHERAPEUTICS INC reported revenue of n/a, net income of −$4.16M and diluted EPS of −$2.94; for the fiscal year ended December 2025 revenue was n/a.
CLDI annual revenue and earnings
- Fiscal year ended Dec 2025: revenue n/a, gross profit n/a, operating income −$20.2M, net income −$19.9M (margin n/a), EPS −$5.95
- Fiscal year ended Dec 2024: revenue n/a, gross profit n/a, operating income −$21.8M, net income −$22.1M (margin n/a), EPS −$35.70
- Fiscal year ended Dec 2023: revenue n/a, gross profit n/a, operating income −$29.0M, net income −$29.2M (margin n/a), EPS −$17.33
- Fiscal year ended Dec 2022: revenue $45.0K, gross profit n/a, operating income −$23.1M, net income −$25.4M (margin -56504.4%), EPS $2.99
CLDI quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$4.16M, EPS −$2.94
- Quarter ended Mar 31, 2026: revenue n/a, net income −$4.11M, EPS −$0.43
- Quarter ended Dec 31, 2025 (from the annual report): revenue n/a, net income −$4.06M, EPS $30.22
- Quarter ended Sep 30, 2025: revenue n/a, net income −$5.15M, EPS −$2.21
- Quarter ended Jun 30, 2025: revenue n/a, net income −$5.72M, EPS −$31.75
- Quarter ended Mar 31, 2025: revenue n/a, net income −$4.99M, EPS −$2.21
- Quarter ended Dec 31, 2024 (from the annual report): revenue n/a, net income −$4.10M, EPS −$9.17
- Quarter ended Sep 30, 2024: revenue n/a, net income −$5.05M, EPS −$7.75
- Quarter ended Jun 30, 2024: revenue n/a, net income −$5.77M, EPS −$16.75
- Quarter ended Mar 31, 2024: revenue n/a, net income −$7.23M, EPS −$2.03
- Quarter ended Dec 31, 2023 (from the annual report): revenue n/a, net income −$8.23M, EPS −$0.93
- Quarter ended Sep 30, 2023: revenue n/a, net income −$2.02M, EPS −$1.41
- Quarter ended Jun 30, 2023: revenue n/a, net income −$12.5M, EPS −$14.24
- Quarter ended Mar 31, 2023: revenue n/a, net income −$6.46M, EPS −$0.75
- Quarter ended Dec 31, 2022 (from the annual report): revenue n/a, net income −$7.76M, EPS n/a
- Quarter ended Sep 30, 2022: revenue n/a, net income −$5.36M, EPS −$0.63
- Quarter ended Jun 30, 2022: revenue n/a, net income −$4.58M, EPS n/a
- Quarter ended Mar 31, 2022: revenue n/a, net income −$7.74M, EPS n/a
- Quarter ended Sep 30, 2021: revenue n/a, net income −$823K, EPS n/a
- Quarter ended Jun 30, 2021: revenue n/a, net income −$83.3K, EPS n/a
CLDI cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$21.3M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$19.7M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$27.0M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$13.2M, share buybacks n/a
CLDI balance sheet
- Jun 30, 2026: cash n/a, total assets $7.20M, total liabilities $4.07M, shareholders' equity $3.13M
- Mar 31, 2026: cash n/a, total assets $9.59M, total liabilities $4.66M, shareholders' equity $4.94M
- Dec 31, 2025: cash n/a, total assets $8.86M, total liabilities $5.10M, shareholders' equity $3.76M
- Sep 30, 2025: cash n/a, total assets $14.0M, total liabilities $6.83M, shareholders' equity $6.92M
- Jun 30, 2025: cash n/a, total assets $9.35M, total liabilities $7.28M, shareholders' equity $1.76M
- Mar 31, 2025: cash n/a, total assets $15.1M, total liabilities $7.77M, shareholders' equity $6.94M
- Dec 31, 2024: cash $9.60M, total assets $14.2M, total liabilities $12.2M, shareholders' equity $1.53M
- Sep 30, 2024: cash $1.90M, total assets $6.66M, total liabilities $16.5M, shareholders' equity n/a
Is CLDI profitable?
No. CALIDI BIOTHERAPEUTICS INC lost $17.5M over the last four quarters.
What is CLDI's EPS?
Diluted earnings per share over the last four quarters were $24.64; −$2.94 in the latest quarter.